<DOC>
	<DOC>NCT01494506</DOC>
	<brief_summary>The study is an open label, randomized phase 3 study of MM-398 with or without 5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and leucovorin in metastatic pancreatic cancer patients who have progressed on prior gemcitabine based therapy.</brief_summary>
	<brief_title>Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas Metastatic disease Documented disease progression after prior gemcitabine based therapy KPS &gt;/= 70 Adequate bone marrow function Adequate hepatic function Adequate renal function Active CNS metastasis Clinically significant GI disorders Severe arterial thromboembolic events less than 6 months before inclusion NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure Active infection or uncontrolled fever Pregnant or breast feeding patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>MM-398</keyword>
	<keyword>PEP02</keyword>
	<keyword>Metastatic pancreatic cancer</keyword>
	<keyword>Gemcitabine refractory pancreatic cancer</keyword>
	<keyword>Second line pancreatic cancer treatment</keyword>
	<keyword>Pancreatic cancer post gemcitabine therapy</keyword>
</DOC>